HIV Glasgow 2022

HIV Glasgow 2022
October 23-26, 2022
Glasgow, Scotland

HIV Drug Therapy Glasgow 2022.

Explore more information for Gilead HIV / AIDS therapies
Results (8)

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study

Risk Factors Associated With ≥ ±10% Weight Change in Treatment-Naïve and Treatment-Experienced People Living With HIV Initiating or Switching to an NNRTI-or INSTI-Based Antiretroviral Therapy in Four Large Cohort Studies

ART regimen persistence among treatment-experienced patients with HIV switching to a MTR or STR since 2018

Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label TAF

Common adverse events in clinical studies of people using lenacapavir for HIV treatment

A pooled analysis of 8 clinical studies suggests a link between influenza-like AEs and pharmacodynamics of the TLR7 agonist VES

Phenotypic Analyses of Clinical Isolates with Capsid Substitutions Observed in People with HIV (PWH) Treated with Lenacapavir

Week 52 Subgroup efficacy analyses of long-acting subcutaneous lenacapavir in Phase 2/3 in heavily treatment-experienced people with multi-drug resistant HIV (CAPELLA study)